Numerous urine and plasma biomarkers have been proposed to predict short and long-term prognosis of AKI among which interleukin-18 (IL-18), cystatine C, neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) or NephrocheckTM, which is the product of tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein-7 (IGFBP7). The gene discussed is IL18; the disease is acute kidney injury.